2024 annual financial data
Sutro Biopharma 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was -308.72%.
Operating income was -238,453,000 USD and net income was -227,461,000 USD.
Operating cash flow was -191,540,000 USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 62,043,000 USD
- Operating income
- -238,453,000 USD
- Net income
- -227,461,000 USD
- Operating cash flow
- -191,540,000 USD